title: Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.
abstract: Autoimmune phenomena are common in both hepatitis C infection and interferon alfa treatment; however, the development of antiphospholipid syndrome is rare. This article reports the case of a patient who developed antiphospholipid syndrome in addition to cutaneous sarcoidosis in the setting of pegylated interferon alfa and ribavirin treatment for hepatitis C.
authors.affiliation: Division of Dermatology, Department of Medicine, University Washington, Medical Center, Seattle, WA 98195-6524, USA. mshinoha@u.washington.edu
authors.forename: Michi M
authors.initials: MM
authors.lastname: Shinohara
authors.forename: Claudia
authors.initials: C
authors.lastname: Davis
authors.forename: John
authors.initials: J
authors.lastname: Olerud
mesh_terms: D016736:Antiphospholipid Syndrome / Q000139:chemically induced*; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000737:chemistry; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012507:Sarcoidosis / Q000139:chemically induced*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012254:Ribavirin